Tag: Heart / Stroke-Related: High Cholesterol
Evolocumab Does Not Impact Cognition in Atherosclerotic CVD
Adding evolocumab to maximally tolerated statin therapy did not affect patient-reported cognition
2015 to 2018 Saw High Total Cholesterol for 11.4 Percent of U.S. Adults
Highest prevalence of high total cholesterol in those aged 40 to 59; prevalence similar by race/ethnicity
Public Policy Recs Updated for Familial Hypercholesterolemia
Goals include enhancing awareness of familial hypercholesterolemia as a global public health issue
APO(a)-LRX Found to Reduce Lipoprotein(a) Levels
Dose-dependent reduction found in patients with elevated lipoprotein(a) levels, cardiovascular disease
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk
Fifty percent reduction in non-HDLC concentration linked to reduced risk for CVD event by age 75 years
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk
Fifty percent reduction in non-HDLC concentration linked to reduced risk for CVD event by age 75 years
AHA: Lower-Target LDL Level Beneficial After Stroke, TIA
Subsequent risk for CV events lower among patients with ischemic stroke, TIA, evidence of atherosclerosis
AHA: Predictors for Meeting LDL-C, SBP Goals ID’d in ISCHEMIA
Older age, male sex, high-intensity statin use, lower baseline LDL-C predict LDL-C goal attainment
AHA: Many With Atherosclerotic CVD Not Meeting LDL-C Goals
Of those patients receiving only a statin, 67.0 percent did not achieve recommended LDL-C goal
Cholesterol Levels Have Been Dropping Since 2013 Guidelines
Total cholesterol, triglycerides, LDL-C levels decreased; proportion of eligible adults taking statins increased
